ArticleJournal of tissue engineering and regenerative medicine2018
PDGF is a potent initiator of bone formation in a tissue engineered model of pathological ossification.
Article in Journal of tissue engineering and regenerative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 48 citations in OpenAlex.
- Cell Senescence in Heterotopic Ossification.Biomolecules · 2024Review
- Engineered myeloid precursors differentiate into osteoclasts and resorb heterotopic ossification in mice.Frontiers in bioengineering and biotechnology · 2024Article
- Preosteoclast plays a pathogenic role in syndesmophyte formation of ankylosing spondylitis through the secreted PDGFB - GRB2/ERK/RUNX2 pathway.Arthritis research & therapy · 2023Article
- Tourniquet use following blast-associated complex lower limb injury and traumatic amputation promotes end organ dysfunction and amplified heterotopic ossification formation.Journal of orthopaedic surgery and research · 2022Article
- E3 ligase HUWE1 promotes PDGF D-mediated osteoblastic differentiation of mesenchymal stem cells by effecting polyubiquitination of β-PDGFR.The Journal of biological chemistry · 2022Article
- Mechanomodulation: Physical Treatment Modalities Employ Mechanotransduction to Improve Scarring.European burn journal · 2022Article
- Controlled Co-delivery of pPDGF-B and pBMP-2 from intraoperatively bioprinted bone constructs improves the repair of calvarial defects in rats.Biomaterials · 2022Article
- Bioactivity Evaluation of Biphasic Hydroxyapatite Bone Substitutes Immersed and Grown with Supersaturated Calcium Phosphate Solution.Materials (Basel, Switzerland) · 2021Article
- Crosstalk between Bone and Nerves within Bone.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Effects of platelet-derived growth factor-BB on cellular morphology and cellular viability of stem cell spheroids composed of bone-marrow-derived stem cells.Biomedical reports · 2020Article
- Osteoimmunology of Oral and Maxillofacial Diseases: Translational Applications Based on Biological Mechanisms.Frontiers in immunology · 2019Review
- PDGF is a potent initiator of bone formation in a tissue engineered model of pathological ossification.Journal of tissue engineering and regenerative medicine · 2018Article
- Spectroscopic profiling variations in extracellular vesicle biochemistry in a model of myogenesis.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Heterotopic ossification (HO) is a debilitating condition defined by the rapid formation of bone in soft tissues. What makes HO fascinating is first the rate at which bone is deposited, and second the fact that this bone is structurally and compositionally similar to that of a healthy adult. If the mechanisms governing HO are understood, they have the potential to be exploited for the development of potent osteoinductive therapies. With this aim, a tissue-engineered skeletal muscle was used model to better understand the role of inflammation on this debilitating phenomenon. It was shown that myoblasts could be divided into two distinct populations: myogenic cells and undifferentiated 'reserve' cells. Gene expression analysis of myogenic and osteoregulatory markers confirmed that 'reserve' cells were primed for osteogenic differentiation but had a reduced capacity for myogenesis. Osteogenic differentiation was significantly enhanced in the presence of platelet-derived growth factor (PDGF)-BB and bone morphogenetic protein 2 (BMP2), and correlated with conversion to a Sca-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.